Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...
Half a year after being spurned by the FDA and following deep layoffs, IO Biotech has decided to close its doors for good. The Danish biotech has ceased operations and said goodbye to its employees, C ...
Biotech has benefited marginally from this rotation. Value beat growth notably in the first quarter. The energy sector was obviously the best performing of the 11 sectors of the S&P 500 in Q1 with a ...
State Street SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB) have delivered strong returns of 40.80% and 33.95% respectively over the trailing year, but their equal-weight versus market ...
U.S. venture capital firms are no longer waiting for Chinese biotech assets to surface before investing in them — they’re moving upstream, embedding themselves inside labs and courting scientists ...
Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The Information and Eric Newcomer. Sources close to the deal confirmed to TechCrunch ...
Have we passed the peak of biotech layoffs? It’s too early to say for certain—but an intriguing story is playing out in the figures. According to an analysis of Fierce Biotech’s layoff data, a total ...
A major biotech company is leaving the Bay Area. Pfizer is abandoning its research site at 181 Oyster Point Blvd. in South San Francisco. The biotech company will move out of the building by the end ...
State Street SPDR S&P Biotech ETF (XBI) gained +40.32% over the past year and equally weights roughly 145 stocks to provide exposure to smaller biotech companies. iShares Biotechnology ETF (IBB) ...
CRISPR Therapeutics is the second largest holding in Cathie Wood's Ark Innovation ETF. Incoming clinical trial data could send the stock soaring this year. Growing sales of Casgevy plus new candidates ...
Large language models trained on vast datasets could speed genomics research, streamline clinical documentation, improve real-time diagnostics, support clinical decision-making, accelerate drug ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The first three months of 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results